经典霍奇金淋巴瘤肿瘤免疫微环境与EB病毒及预后相关性研究

项目名称： 经典霍奇金淋巴瘤肿瘤免疫微环境与EB病毒及预后相关性研究

项目编号： No.81201859

项目类型： 青年科学基金项目

立项/批准年度： 2013

项目学科： 淋巴瘤及其他淋巴增殖性疾病

项目作者： 黄欣

作者单位： 北京大学

项目金额： 23万元

中文摘要： 经典霍奇金淋巴瘤（cHL）是一组临床生物学行为异质性明显的肿瘤，目前尚无明确能评估cHL危险度的生物学标记。cHL有着极其丰富和复杂的炎性背景，肿瘤细胞与周围炎症细胞的"对话"机制一直是cHL的研究热点，它不仅对肿瘤的演进起到了不可忽视的重要作用，且近来的研究发现其中的免疫活性细胞成分及功能状态如肿瘤浸润淋巴细胞和肿瘤相关巨噬细胞等，均与预后相关，但这些结果尚需要更多的研究来予以验证。在我国此方面的研究明显滞后，本研究旨在1）比较分析EBV阳性和阴性经典霍奇金淋巴瘤肿瘤微环境内不同亚群浸润淋巴细胞和巨噬细胞分布情况，探讨EBV感染对局部免疫状态的作用；2）结合临床特点，经单因素或多因素分析肿瘤背景中不同免疫细胞亚群的浸润密度对预后的提示意义，初步探寻有意义的预后预测生物学标记，以更好指导临床的个体化治疗。

中文关键词： 经典霍奇金淋巴瘤；EB病毒；肿瘤相关巨噬细胞；PDL-1；预后

英文摘要： The behavior of classical Hodgkin lymphoma (cHL) was determined by both the intrinsic features of the tumor cells and the characteristics of the microenvironment. In the last few years,an increasing evidence suggests that the tumor immune microenvironment is of prognostic significance in a variety of human maligancies including cHL. For now, cHL patients were assigned to be early or advanced disease based on Ann Arbor staging system and treatment is tailored accordingly. The prognosis of cHL patients substantially improved during the last three decades. However, cHL is clinically heterogeneous that patients with early disease were not consistently associated with a good prognosis.The prognosis of relapsed and refractory cHL patients was poor with a 5-year survival rate of less than 30%. Previous studies proposed that the number of tumor associated macrophages might be a potential biomarkers for the risk prediction in cHL. However,the studies conducted to date were mainly performed in western cHL patients population and were modest in size. Currently, nothing is know in this regard for the Chinese cHL patients. Hence we plan to conduct a pioneering study to investigate the immune cell populations in the tumor microenvironment of cHL in the Chinese population and assess the association of the infiltration intensi

英文关键词： Classical Hodgkin lymphoma；Epstein Barr virus；tumor associated macrophage；PDL-1；prognosis